Argenx Surges to 319th in Trading Volume as FDA Approves New Self-Injection Option for VYVGART Hytrulo

On April 11, 2025, Argenx (ARGX) saw a significant surge in trading volume, reaching 3.10 billion, marking a 31.68% increase from the previous day. This surge placed Argenx at the 319th position in terms of trading volume for the day. The stock price of Argenx also rose by 6.36%.

Argenx recently announced that the U.S. Food and Drug Administration (FDA) has approved a new self-injection option for VYVGART Hytrulo, a first-in-class FcRn blocker. This approval includes a prefilled syringe, providing patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) an additional administration method. This development is expected to enhance patient convenience and accessibility to treatment.

The FDA's approval of the prefilled syringe version of VYVGART Hytrulo is a significant milestone for Argenx. This new option is designed for adult patients with gMG who are anti-AChR antibody positive, as well as adults with CIDP. The self-injection feature is anticipated to improve the quality of life for patients by offering a more flexible and user-friendly treatment method.

Argenx's announcement of the FDA approval for VYVGART Hytrulo's self-injection option underscores the company's commitment to innovation and patient care. The approval of the prefilled syringe version is a testament to Argenx's efforts in developing advanced therapeutic solutions for patients with immune-mediated diseases. This development is likely to have a positive impact on the company's market position and investor confidence.